Surrey Heartlands

Joint Formulary & PAD

Tamoxifen citrate - Prostate cancer

You are here : Home > Formulary Search > Tamoxifen citrate - Prostate cancer

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

Off-label use. Gynaecomastia prevention in men undergoing long-term bicalutamide treatment, if radiotherapy unsuccessful

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tamoxifen citrate
Indication :
Prostate cancer
Group Name :
Keywords :
Gynaecomastia, breast buds, NICE, prostate cancer
Brand Names Include :
Soltamox
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Tamoxifen citrate is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Prostate cancer.

Committee Recommendations (1)

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The use of tamoxifen for prevention of gynaecomastia in men undergoing treatment for prostate cancer is an off-label indication and traffic light status has yet to be considered by the APC.

NICE guidance is clear that patients should have been offered prophylactic radiotherapy to both breast buds within the first month of treatment with bicalutamide. Weekly tamoxifen (20mg) could then be considered if radiotherapy does not prevent gynaecomastia

Primary care prescribers should have confirmation that the patient has been treated in line with NICE guidance (NG131) before agreeing to prescribe. https://www.nice.org.uk/guidance/ng131/resources/prostate-cancer-diagnosis-and-management-pdf-66141714312133